from journal Lancet
Asthma affects almost three hundred million people around the world. Severe asthma may affect as many as fifteen million. For those comes breakthrough news. Using biologic treatments without additional high-dose inhaled steroids controls severe asthma AND minimizes or eliminates unpleasant and often serious side-effects. The biologic tested in this study is one that is easier to read than pronounce—benralizumab. The research, while funded by Astrazeneca, was done at renowned universities, including Kings College, Queens University Belfast, and Trinity College Dublin, and published in the journal Lancet. Authors urge additional studies on the effectiveness of a wider range of biologic treatments.